Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : John Pitera's Market Laboratory -- Ignore unavailable to you. Want to Upgrade?

To: GROUND ZERO™ who wrote (283)	3/1/2000 10:46:00 PM
From: John Pitera	Read Replies (1) \| Respond to of 33421

Paul, with NMPS, it looks like they have been working on these screening techniques for several years and they are just reaching critical mass this past year. In terms of getting more clinical test results with favorable outcomes, being granted key patents, which are necessary to profit from this screening process. etc I have looked at that multi-year chart many times, and one would think it's time to sell some stock up near the multi-year high of 15. NMPS's research Nuclear Protein Matrix screening is also used to detect bladder, cervical, prostate as well as potentially, many other cancers. NMPS has also clearly been a beneficiary of the renewed interest in biotech stocks that has been spurred on by the great developments occurring in the human genome stocks. John